Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymeric micelles + fruquintinib in second-line advanced gastric cancer
ChiCTR2500096559Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and fruquintinib in gastric cancer (GC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival. Started Jan 2025; status: recruiting.
02
Drugs
paclitaxelfruquintinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2500096559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096559.